These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20043314)

  • 21. Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764).
    Wager TT; Pettersen BA; Schmidt AW; Spracklin DK; Mente S; Butler TW; Howard H; Lettiere DJ; Rubitski DM; Wong DF; Nedza FM; Nelson FR; Rollema H; Raggon JW; Aubrecht J; Freeman JK; Marcek JM; Cianfrogna J; Cook KW; James LC; Chatman LA; Iredale PA; Banker MJ; Homiski ML; Munzner JB; Chandrasekaran RY
    J Med Chem; 2011 Nov; 54(21):7602-20. PubMed ID: 21928839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.
    Zhou D; Gross JL; Adedoyin AB; Aschmies SB; Brennan J; Bowlby M; Di L; Kubek K; Platt BJ; Wang Z; Zhang G; Brandon N; Comery TA; Robichaud AJ
    J Med Chem; 2012 Mar; 55(5):2452-68. PubMed ID: 22313242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists.
    Wieland K; Bongers G; Yamamoto Y; Hashimoto T; Yamatodani A; Menge WM; Timmerman H; Lovenberg TW; Leurs R
    J Pharmacol Exp Ther; 2001 Dec; 299(3):908-14. PubMed ID: 11714875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benzo[b]thiophene-2-carboxamides and benzo[b]furan-2-carboxamides are potent antagonists of the human H3-receptor.
    Peschke B; Bak S; Hohlweg R; Nielsen R; Viuff D; Rimvall K
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3162-5. PubMed ID: 16616493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in histamine H3 receptor antagonists/inverse agonists.
    Łazewska D; Kieć-Kononowicz K
    Expert Opin Ther Pat; 2010 Sep; 20(9):1147-69. PubMed ID: 20716022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines.
    Apodaca R; Dvorak CA; Xiao W; Barbier AJ; Boggs JD; Wilson SJ; Lovenberg TW; Carruthers NI
    J Med Chem; 2003 Aug; 46(18):3938-44. PubMed ID: 12930154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a selective and potent radioactive ligand for histamine H(3) receptors: A compound potentially useful for receptor occupancy studies.
    Mitobe Y; Ito S; Mizutani T; Nagase T; Sato N; Tokita S
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4075-8. PubMed ID: 19553110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.
    Zaragoza F; Stephensen H; Peschke B; Rimvall K
    J Med Chem; 2005 Jan; 48(1):306-11. PubMed ID: 15634025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Azole derivatives as histamine H3 receptor antagonists, part I: thiazol-2-yl ethers.
    Walter M; von Coburg Y; Isensee K; Sander K; Ligneau X; Camelin JC; Schwartz JC; Stark H
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5879-82. PubMed ID: 20728354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and three-dimensional quantitative structure-activity relationship analysis of H3 receptor antagonists containing a neutral heterocyclic polar group.
    Rivara S; Mor M; Bordi F; Silva C; Zuliani V; Vacondio F; Morini G; Plazzi PV; Carrupt PA; Testa B
    Drug Des Discov; 2003; 18(2-3):65-79. PubMed ID: 14675944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders.
    Troxler T; Feuerbach D; Zhang X; Yang CR; Lagu B; Perrone M; Wang TL; Briner K; Bock MG; Auberson YP
    ChemMedChem; 2019 Jul; 14(13):1238-1247. PubMed ID: 30957954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel H3 receptor antagonists with improved pharmacokinetic profiles.
    Santora VJ; Covel JA; Hayashi R; Hofilena BJ; Ibarra JB; Pulley MD; Weinhouse MI; Semple G; Ren A; Pereira G; Edwards JE; Suarez M; Frazer J; Thomsen W; Hauser E; Lorea J; Grottick AJ
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4133-6. PubMed ID: 18554904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-activity relationships of arylbenzofuran H3 receptor antagonists.
    Gfesser GA; Faghih R; Bennani YL; Curtis MP; Esbenshade TA; Hancock AA; Cowart MD
    Bioorg Med Chem Lett; 2005 May; 15(10):2559-63. PubMed ID: 15863316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The histaminergic system: a target for innovative treatments of cognitive deficits].
    Motawaj M; Burban A; Davenas E; Gbahou F; Faucard R; Morisset S; Arrang JM
    Therapie; 2010; 65(5):415-22. PubMed ID: 21144476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyrrolidin-3-yl-N-methylbenzamides as potent histamine 3 receptor antagonists.
    Zhou D; Gross JL; Sze JY; Adedoyin AB; Bowlby M; Di L; Platt BJ; Zhang G; Brandon N; Comery TA; Robichaud AJ
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5957-60. PubMed ID: 21843941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
    Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists.
    Cole DC; Gross JL; Comery TA; Aschmies S; Hirst WD; Kelley C; Kim JI; Kubek K; Ning X; Platt BJ; Robichaud AJ; Solvibile WR; Stock JR; Tawa G; Williams MJ; Ellingboe JW
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1237-40. PubMed ID: 20042333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histamine H3 receptor as a drug discovery target.
    Berlin M; Boyce CW; Ruiz Mde L
    J Med Chem; 2011 Jan; 54(1):26-53. PubMed ID: 21062081
    [No Abstract]   [Full Text] [Related]  

  • 39. Dibasic biphenyl H3 receptor antagonists: Steric tolerance for a lipophilic side chain.
    Bordi F; Rivara S; Dallaturca E; Carmi C; Pala D; Lodola A; Vacondio F; Flammini L; Bertoni S; Ballabeni V; Barocelli E; Mor M
    Eur J Med Chem; 2012 Feb; 48():214-30. PubMed ID: 22222138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
    Hancock AA
    Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.